Trial Profile
SCH 52365 [Temozolomide] Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Schering-Plough
- 21 Feb 2013 Trial company changed from Schering-Plough to Merck and Co as reported by ClinicalTrials.gov.
- 12 Jun 2008 New trial record.